Lung & Respiratory Health Updates: CF Drug Approvals, RSV Breakthroughs, COVID-19 Patents & TB Access Wins 🫁🌍
In this week’s roundup of game-changing developments in lung and respiratory care, we cover breakthrough treatments, global access wins, and regulatory momentum. From cystic fibrosis to RSV and drug-resistant TB, these updates highlight the global push to transform respiratory outcomes.
💊 Vertex’s ALYFTREK® Gets CHMP Green Light
A new CFTR modulator for cystic fibrosis patients aged six and above shows superior sweat chloride reduction compared to KAFTRIO®. This could expand access for those with non-class I mutations across Europe.
👶 Beyfortus® Launches in India for RSV Prevention
Dr. Reddy’s and Sanofi team up to introduce the first RSV preventive therapy for all infants, with protection across two RSV seasons. Launch aligns with World Immunization Week.
🌏 RedHill Biopharma Secures Patent in China for COVID-19 Drug
RHB-107, an oral antiviral, receives a key patent grant in China. U.S. Phase 2 trials showed a reduction in hospitalizations of one hundred percent—boosting RedHill’s IP strategy in Asia.
💸 Pretomanid TB Drug Price Cut by 25 Percent
Global Drug Facility drops the cost to $169 per course—less than $1 per day—making treatment for drug-resistant TB 47 percent cheaper than in 2022 and significantly more accessible.
📢 Stay Ahead in Lung & Respiratory Health Research!
✅ Like, share, and subscribe for weekly updates on lung and respiratory health
#CysticFibrosis #RSV #COVID19Treatment #DrugResistance #GlobalHealth #CFTRModulators #ALYFTREK #Beyfortus #Nirsevimab #Pretomanid #Tuberculosis #RespiratoryInnovation #RedHillBiopharma #VertexPharma #Sanofi #DrReddys #PharmaNews #LungHealth #LucidQuest #PulmonaryUpdates #HealthcareAccess #ClinicalBreakthroughs #RespiratoryCare #BiopharmaUpdates